Abstract
The benefit/risk ratio of immuno-oncology (I–O) agents is crucial when considering treatment options for cancer patients. Highly potent and targeted oncology agents come with high hopes of patient benefit. The tradeoff that comes with greater potency is the potential for serious and life-threatening toxicity, such as cytokine release syndrome (CRS). It is incumbent upon physicians, drug developers, and all other stakeholders to ensure a benefit/risk profile for these drugs that optimizes the patient experience throughout their treatment journey, iterating on mitigation measures that work while continuing to explore interventions that might further reduce risk of CRS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
